tralokinumab AD
Selected indexed studies
- Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). (Br J Dermatol, 2021) [PMID:33000465]
- Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. (J Allergy Clin Immunol, 2023) [PMID:37678577]
- Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. (J Allergy Clin Immunol, 2019) [PMID:29906525]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). (2021) pubmed
- Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. (2019) pubmed
- Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. (2023) pubmed
- Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. (2024) pubmed
- Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs. (2024) pubmed
- Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. (2022) pubmed
- Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial. (2023) pubmed
- Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years. (2024) pubmed
- Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. (2021) pubmed
- Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis. (2025) pubmed